Severe pulmonary toxicity in a patient treated with gemcitabine.
Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.
Rosado
Manuel F
MF
Department of Medicine, Jackson Memorial Hospital, University of Miami School of Medicine, 1611 NW 12th Avenue, Miami, FL 33136-1094, U.S.A.
Kett
Daniel H
DH
Schein
Roland M H
RM
Baraona
Francisco J
FJ
Sridhar
Kasi S
KS
D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D004417:Dyspnea / Q000139:chemically induced; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine